Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Ubrelvy (ubrogepant) and Nurtec (rimegepant) are prescription medications approved to help manage and offer relief for people dealing with migraine headaches with or without aura. Both belong to a ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 ...

Rimegepant 75mg; orally disintegrating tabs (ODT). Concomitant strong CYP3A4 inhibitors: Avoid use with Nurtec ODT. Concomitant moderate CYP3A4 inhibitors: Avoid another dose of Nurtec ODT within ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Of her decision to partner with Nurtec, Khloé reveals that she started getting migraines at the age of 12 and had "tried everything" to deal with the "completely debilitating" pain that would ...

In the prevention end of the migraine market, Qulipta will have to compete most closely with Biohaven's Nurtec ODT (rimegepant), approved by the FDA for prevention of episodic migraine in May and ...

Jared S. Hopkins is a New York-based reporter for The Wall Street Journal, where he covers healthcare and pharmaceutical ...

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future ...